SNT

2.27%

4.3¢ syntara limited

Ann: Investor presentation, page-43

First 43 Last

Share
Profile

Follow
FreeBobby2002

890 Posts.

469

10/07/24

12:22

Post #: 74688653
Share

Originally posted by Grainofsand: ↑

You've probably seen this video already, but if you haven't -

Apart from what you already mention, another key catalyst will be the interim trial results for the SNT-5505 Phase 2amyelofibrosiscombination study, which is almost fully recruited for (80% there), locked in to be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. Likely to be a significant inflection point and an opportunity to raise money at a premium, if required.

My primary reasons for investing:
- 1 year cash runway
- 3 or 4 different Phase 2 trial results all due by mid-2025
- Positive data from SNT 5505 monotherapy study! It's interim Ph2 data is due in Dec '24 as mentioned above
- SNT 5505 - demonstrated reduction in bone marrow fibrosis AND demonstrated improvement in scar appearance
- Company has worked with Fiona Wood for 5 years on scar treatment. There are no other pharma treatments in development and Fiona Wood saw the full inhibition of L enzymes, and the 30% reduction of collagen in scars, over only a 3-month period, as UNPRECEDENTED! Trial patients still continue to improve after the end of the trial.
- Management have taken serious steps to reduce costs and stretch funds
- $10m raised late last year from institutions at 2.2c. Platinum Investments increasing their holding from 8-20%. As a friend of mine said - these institutions employ people to do due diligence on their investments - if an investment is good enough for them, then it's good enough for me!
- I haven't checked but CEO advises of a super strong register of investors with 60% being instos
- Focus by company - cancer of the blood and skin scarring
- Huge potential market for just one of these products, let alone more than one. I think market exposure for all was something like $15b!
- Some people, who I value as knowing a lot more about bios than myself, think SNT is an exceptional buying opportunity! Works for me!

Expand

Very impressive delivery, no BS style, I like it. Thanks for tagging me here @ma420 and please feel free to in future if you're ever interested in a specific stock!

Will look deeper into this in the coming days and hopefully buy in. Really liking the small market cap, impending milestones, and high % of instos on the registry.

SNT Price at posting: 3.0¢ Sentiment: None Disclosure: Not Held
4 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 1 more message in this thread...

First 43 Last

Add SNT (ASX) to my watchlist

(20min delay)
Last 4.3¢		Change -0.001(2.27%)		Mkt cap ! $59.04M

Open	High	Low	Value	Volume
4.4¢	4.4¢	4.2¢	$39.11K	895.4K

Buyers (Bids)

No.	Vol.	Price($)
1	752779	4.3¢

Sellers (Offers)

Price($)	Vol.	No.
4.4¢	200000	1

View Market Depth

No.	Vol.	Price($)
1	752779	0.043
1	590	0.042
3	1060000	0.041
8	1482500	0.040
1	200000	0.039

Price($)	Vol.	No.
0.044	200000	1
0.045	591528	2
0.046	142712	2
0.049	68444	2
0.050	20000	1

Last trade - 15.58pm 04/10/2024 (20 minute delay)

SNT (ASX) Chart

Ann: Investor presentation, page-43

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor presentation, page-43

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News